Andrew joined Abingworth in 2008 with previous experience as an equity analyst in the pharmaceutical and biotechnology sectors. At Abingworth, he works across multiple strategies, including CCD, private investing and specialises in evaluating opportunities in public companies including VIPE investments. He heads up our Publics and Late Stage strategies, is fund manager for open market transactions and represents Abingworth on the boards of Adicet Bio, Entact Bio, Ascend, Soleno and Timberlyne. He was also an observer on the boards of HilleVax and Phathom.
Immediately prior to Abingworth, Andrew worked for HSBC Global Markets, where he was Senior Equity Analyst, Director, responsible for investment research in the mid-cap pharmaceutical sector and before this was at Credit Suisse and SG Cowen.
Andrew completed a PhD in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich, and holds a BSc in Microbiology from King’s College London. Andrew qualified as a chartered accountant with KPMG.
